GlassScriptPhysician profile
Cody T Ott
NPI 1528453156
$3,737.83
in general payments reported to CMS, 2019-2025
19 companies · $1,273 in 2025
The $1,273 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $458 · 2020: $234 · 2021: $315 · 2022: $400 · 2023: $580 · 2024: $479 · 2025: $1,273.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,300 · Entertainment: $31.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,299.81 |
| Entertainment | $31.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $737.22 | 2019-2025 | Clareon, Clareon Panoptix Pro, Rocklatan |
| Abbvie INC. | $531.31 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $374.44 | 2022-2025 | Xiidra, Vyzulta, Miebo |
| Novartis Pharmaceuticals Corporation | $345.01 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $304.33 | 2019-2025 | Cequa |
| Aerie Pharmaceuticals, INC. | $225.26 | 2019-2021 | |
| Harrow Eye, LLC | $217.53 | 2025 | Vevye |
| Dompe US, INC. | $200.22 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $186.38 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $171.77 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Allergan, INC. | $77.05 | 2020-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $76.26 | 2020-2021 | |
| Eyevance Pharmaceuticals LLC | $72.83 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $70.85 | 2021-2024 | Acthar |
| Ocular Therapeutix, INC. | $45.94 | 2021-2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nova Eye, INC. | $31.81 | 2025 | |
| Rxsight INC | $27.93 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Horizon Therapeutics Plc | $20.91 | 2022 | |
| Sight Sciences, INC. | $20.78 | 2025 | Omni Surgical System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cody Ott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.